Research advances, once they have been thoroughly tested and approved, only help our patients if they have access to them. We are working to make complex care more readily available in communities closer to where our patients live, and we are cultivating our evidence-based eHealth and telemedicine programs to further transform and expand how we care for patients.
Today's care increasingly combines the expertise of specialties within ophthalmology and with other fields of medicine. By also drawing upon the knowledge and skills of our colleagues in other disciplines outside of medicine, we can continue to create better systems that improve patient safety and effectiveness of care.
retinal surgeon, serves as principal investigator of several ongoing therapeutic trials. "Ultimately, we want these therapies to be available for our youngest patients," he explains. "The sooner they receive treatment, the less vision loss they may have to endure." Dr. Jayasundera is the principal investigator on research that precedes clinical testing, called natural history studies Kellogg is currently conducting gene therapy clinical trials and natural history studies for a range of inherited retinal conditions. Dr. Besirli is excited to be part of the group bringing gene therapy to patients at Kellogg. "For so long, we've struggled to help patients facing these blinding illnesses," he says. "Gene therapy is still in its infancy, but there is reason for optimism.
We have an FDA-approved treatment for one condition and numerous promising options for others. We have an outstanding retinal dystrophy team, and we have amazing patients. It's a very exciting time."
Cagri Besirli, MD, PhD above: Naheed Khan, PhD, meets with a Emma as she undergoes testing.
below: Kari Branham, MS, CGC, meets with Emma and her family to help determine if she is eligible for the treatment The KCRC has more than realized that vision. Since In developing nations, Thulsi estimates that for every patient that seeks care, four or five do not, and for every patient who receives treatment advice, as many as half may not follow through with the recommended surgery, medication or glasses.
Changing these statistics requires a dramatic change in perspective, he argues. "If you don't own the problem, you won't make a difference."
The success of Aravind in India is a story of owning the problem. Thulsi described how Aravind has transformed their approach to these issues by eliminating barriers to care, including rethinking the costs of care to better reflect opportunity costs-food, transportation and lost wages-and how the hospital views the delivery of care as a moral imperative. "To deliver the best care," says Dr. Higginbotham, "we need to think broadly and use evidence mindfully. We need to see our patients as far more than the symptoms they present.
We need to unpack the hidden factors driving not just our patients, but our colleagues, our communities and ourselves." poor wound healing that leads to chronic foot ulcers.
This approach is novel in the field of diabetic retinopathy.
To date, research has focused on how diabetes damages the retina. These U-M researchers are instead exploring how inadequate healing may contribute to the disease process.
Unlike impaired foot wound healing in diabetes, however, the retinal vasculature also requires a functioning blood-retinal barrier (BRB) that must be restored for proper vessel function. • Accelerate breakthrough discovery
• Invest in visionary leaders
• Create revolutionary environments for patient care, research, and education
• Invent new models of patient care and education Campaign highlights included:
• Annual fund donors made contributions to the W.K. Kellogg Eye Center that together helped develop a new drug to save cells essential to vision.
• In celebrating the life of its founder, a foundation supported glaucoma faculty and research, investments that today are funding research that will help physicians better tailor treatments to specific patients.
• A forward-looking couple made a targeted contribution to eye cancer, enabling the director of our growing program to pursue innovative research through national and international partnerships.
• Alumni made generous gifts and bequests to launch an Alumni Legacy Fund that will help Kellogg remains a leader in the field for generations to come. 
Accelerating Progress and Promise
As of Nov. 6, total campaign gifts to the Kellogg Eye Center included:
• $37.6 million for research aimed at curing, preventing, and more effectively treating eye disease
• $14 million for faculty support, enabling us to recruit and retain the best ophthalmologists and vision scientists
• $11.7 million for programmatic support, including gifts to fuel innovation in education, patient care, clinical research, and international ophthalmology
With Gratitude to Our Campaign Leadership Council
The following volunteers played a key role in our success. We appreciate their guidance, generosity, and partnership.
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